GDC-6599

• UNSPSC Description:

  GDC-6599 is an orally active TRPA1 inhibitor, with IC50 values of 5.3 nM in humans, 6.6 nM in rats, 9.3 nM in dogs, 7.2 nM in monkeys, and 15 nM in guinea pigs. GDC-6599 can be used in the research of neuropathic pain and respiratory diseases such as asthma and chronic cough[1].

• Target Antigen:

  TRP Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/gdc-6599.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1C2=C(N=CN2C)N=C(N1CC3=NC([C@H]4C[C@H](C5=CC=C(C=C5)Cl)OC4)=NO3)C

• Molecular Weight:

  426.86

• References & Citations:

  [1]Terrett JA, et al. Discovery of TRPA1 Antagonist GDC-6599: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory Disease. J Med Chem. 2024 Mar 14;67(5):3287-3306. doi: 10.1021/acs.jmedchem.3c02121. Epub 2024 Mar 3. PMID: 38431835.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  Phase 2

• CAS Number:

  2376824-99-4